Literature DB >> 7264559

Treatment by limited surgery and specific immunization of guinea pigs with stage II experimental cancer.

J T Hunter, M P Ashley, S Sukumar, T Sugimoto, B Zbar, H J Rapp, E Yarkoni.   

Abstract

The malignant disease produced in guinea pigs by intradermal inoculation of line-10 was allowed to progress to stage II, at which time the dermal tumor and the first draining lymph node were grossly evident. At that stage, the external appearance of the next draining lymph node was normal, but it contained tumor cells. Limited surgery consisting of excision of the dermal tumor and first draining lymph node was not curative; palpable metastases developed in the second and other draining lymph nodes, and at autopsy, some animals were found to have gross, visible lung metastases. Immunization of guinea pigs with a mixture of irradiated syngeneic tumor cells plus mycobacterial cell walls in an oil-in-water emulsion eradicated tumor cells remaining in lymph nodes after limited surgery for stage II experimental cancer and prevented progression of the disease to stage III. Tumor intravenously implanted in the lungs of animals after limited surgery for stage II disease was also eliminated by immunization.

Entities:  

Mesh:

Year:  1981        PMID: 7264559      PMCID: PMC2186431          DOI: 10.1084/jem.154.2.253

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

1.  Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.

Authors:  J M Jessup; C W Riggs; M G Hanna
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

Review 2.  BCG in tumor immunotherapy.

Authors:  R W Baldwin; M V Pimm
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3.

Authors:  I Azuma; E E Ribi; T J Meyer; B Zbar
Journal:  J Natl Cancer Inst       Date:  1974-01       Impact factor: 13.506

4.  Adjuvants for a tumor-specific vaccine: Bordetella pertussis or mycobacterial cell walls attached to oil droplets.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1973-05       Impact factor: 13.506

5.  Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1972-06       Impact factor: 13.506

6.  Eradication by immunization with mycobacterial vaccines and tumor cells of microscopic metastases remaining after surgery.

Authors:  B Zbar; G Canti; M P Ashley; H J Rapp; J T Hunter; E Ribi
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

7.  Adjuvant-antigen requirements for active specific immunotherapy of microscopic metastases remaining after surgery.

Authors:  M P Ashley; B Zbar; J T Hunter; H J Rapp; T Sugimoto
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

8.  Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery.

Authors:  M G Hanna; L C Peters
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

9.  Active, specific immunotherapy of murine leukemia. II. Adjuvant effect of Corynebacterium parvum.

Authors:  G L Bartlett; J W Kreider
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

10.  Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells.

Authors:  R Bomford
Journal:  Br J Cancer       Date:  1975-11       Impact factor: 7.640

View more
  2 in total

1.  Eradication of microscopic hepatic metastases by active specific immunization.

Authors:  S Sukumar; J T Hunter; N Terata; H J Rapp
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  A specific vaccine effective against stage I and stage II malignant disease in guinea pigs. Effect of variations in preparations and storage.

Authors:  E Yarkoni; J T Hunter; S Sukumar
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.